예측 검사 및 증상전 검사 시장 예측( -2030년) : 유형별, 적응증별, 기술별, 샘플별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Predictive Presymptomatic Testing Market is accounted for $5.6 billion in 2024 and is expected to reach $10.9 billion by 2030 growing at a CAGR of 11.6% during the forecast period. Predictive presymptomatic testing is a genetic method used to identify individuals at risk of developing a specific hereditary condition before symptoms appear. It analyzes DNA to detect mutations or markers associated with certain diseases, such as Huntington's disease, certain cancers, and cardiovascular or neurodegenerative disorders. This testing estimates the likelihood of developing a condition in the future; enabling proactive measures like lifestyle changes and increased surveillance.

According to the article published by Frontiers in 2021, in Japan, the rare hereditary disease prevalence was equivalent to less than 1 in 2,500 people.

Market Dynamics:

Driver:

Increasing awareness and incidence of hereditary diseases

As more individuals become aware of their genetic predispositions, there is a growing demand for early testing to enable timely interventions. The increasing prevalence of hereditary conditions such as cancer, cardiovascular diseases, and neurological disorders has further amplified the need for predictive testing. Government initiatives and public health campaigns aimed at promoting genetic literacy also contribute to market growth. Additionally, the growing acceptance of preventive healthcare practices is driving the adoption of predictive presymptomatic testing worldwide.

Restraint:

Ethical and psychological concerns

Many individuals fear the potential psychological burden of knowing their genetic risks, which can lead to anxiety and stress. Ethical dilemmas, including the potential misuse of genetic information by insurers or employers, also pose challenges to market growth. Moreover, concerns about the accuracy of test results and the implications of false positives or negatives add to the hesitancy. Cultural and societal stigma around hereditary diseases further restricts the widespread adoption of these tests hampering the growth of the market.

Opportunity:

Advancements in genetic testing technologies

Innovations such as next-generation sequencing (NGS) and CRISPR-based techniques have enhanced the accuracy, speed, and affordability of genetic testing. These technologies enable comprehensive analysis of genetic variants associated with hereditary diseases, allowing for personalized risk assessment. The integration of artificial intelligence (AI) and big data analytics further supports predictive modeling and enhances the clinical utility of testing. The development of direct-to-consumer genetic testing kits also widens access, creating new avenues for market growth.

Threat:

Accuracy and reliability concerns

Variability in test results due to differences in testing methodologies and laboratory standards undermines consumer trust. False positives or negatives can lead to inappropriate medical decisions, further impacting patient outcomes. The lack of universal regulatory frameworks for genetic testing exacerbates these challenges, creating disparities in test quality across regions. Additionally, the complexity of interpreting genetic data requires specialized expertise, which may not always be available. These factors collectively threaten the market's growth potential and underscore the need for robust quality assurance measures.

Covid-19 Impact

The Covid-19 pandemic significantly influenced the predictive presymptomatic testing market. On one hand, disruptions in healthcare systems and diagnostic services delayed testing procedures and reduced patient access to routine screenings. On the other hand, the pandemic underscored the importance of preventive healthcare, spurring interest in genetic testing for early disease detection. As the world transitions to a post-pandemic phase, the market is poised for recovery and growth, driven by renewed focus on preventive health measures.

The genetic testing segment is expected to be the largest during the forecast period

The genetic testing segment is expected to account for the largest market share during the forecast period owing to early diagnosis and intervention for hereditary diseases. Technological advancements and growing awareness about genetic risks have spurred the adoption of these tests. Furthermore, the availability of non-invasive testing methods, like saliva-based genetic testing, has made predictive presymptomatic tests more accessible and affordable.

The next-generation sequencing (NGS) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the next-generation sequencing (NGS) segment is predicted to witness the highest growth rate due to rapid evolution of genomic medicine and the rise in hereditary disease incidence are factors contributing to this trend. This segment encompasses tests for a variety of conditions, including cancers, cardiovascular diseases, and neurological disorders, all of which benefit from early identification and intervention. The increasing availability of affordable genetic testing options is also expected to drive substantial growth in this segment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to well-established healthcare infrastructure, and there is a high demand for genetic testing due to increasing awareness and a growing number of individuals seeking personalized healthcare. Furthermore, the presence of leading research institutions and biotech companies specializing in genetic testing technologies contributes to North America's dominant market share. Government policies promoting genetic literacy and personalized healthcare are also expected to play a significant role in North America's continued market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by advancements in healthcare infrastructure, rising disposable incomes, and an increasing focus on preventive healthcare. Additionally, countries like China and India are experiencing significant growth in genetic research and testing capabilities, driven by both government investments and private sector initiatives. As awareness around hereditary diseases and genetic testing increases, demand for predictive presymptomatic tests is likely to surge in this region, particularly in urban centers with access to cutting-edge healthcare services.

Key players in the market

Some of the key players in Predictive Presymptomatic Testing market include 23andMe, Abbott Laboratories Inc, Quest Diagnostics Inc, Positive Bioscience, Color Genomics, Gene by Gene, Mapmygenome, Myriad Genetics, BioAxis DNA Research Center Private Limited, Direct Laboratory Services LLC, Pathway Genomics Corporation, Ambry Genetics Corporation, Akonni Biosystems, Element Biosciences, Eurofins Scientific and NGeneBio.

Key Developments:

In January 2024, 23andMe Holding Co. announced the launch of Discover23(R), a new research offering enabling authorized collaborators to securely access the power and diversity of the 23andMe research cohort through a Trusted Research Environment (TRE) developed by Lifebit.

In December 2024, Abbott announced it has reached an agreement with DexCom, Inc. to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.

In December 2024, Quest Diagnostics launched health coaching on questhealth.com to help individuals take control of their health. The holistic programs focus on several key areas, including general health, weight management, chronic kidney disease, type 2 diabetes, or high cholesterol.

Types Covered:

• Genetic Testing
• Biochemical Testing
• Molecular Testing
• Other Types

Indications Covered:

• Oncology
• Neurological Disorders
• Cardiovascular Disorders
• Endocrine Disorders
• Inherited Conditions
• Other Indications

Technologies Covered:

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray Technology
• Fluorescent In Situ Hybridization (FISH)
• Other Technologies

Samples Covered:

• Blood
• Saliva
• Tissue Biopsy
• Other Samples

End Users Covered:

• Hospitals
• Diagnostic Laboratories
• Research & Academic Institutions
• Specialty Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Predictive Presymptomatic Testing Market, By Type

• 5.1 Introduction
• 5.2 Genetic Testing
  • 5.2.1 Single-Gene Testing
  • 5.2.2 Whole Genome Sequencing
  • 5.2.3 Whole Exome Sequencing
• 5.3 Biochemical Testing
• 5.4 Molecular Testing
• 5.5 Other Types

6 Global Predictive Presymptomatic Testing Market, By Indication

• 6.1 Introduction
• 6.2 Oncology
• 6.3 Neurological Disorders
• 6.4 Cardiovascular Disorders
• 6.5 Endocrine Disorders
• 6.6 Inherited Conditions
• 6.7 Other Indications

7 Global Predictive Presymptomatic Testing Market, By Technology

• 7.1 Introduction
• 7.2 Next-Generation Sequencing (NGS)
• 7.3 Polymerase Chain Reaction (PCR)
• 7.4 Microarray Technology
• 7.5 Fluorescent In Situ Hybridization (FISH)
• 7.6 Other Technologies

8 Global Predictive Presymptomatic Testing Market, By Sample

• 8.1 Introduction
• 8.2 Blood
• 8.3 Saliva
• 8.4 Tissue Biopsy
• 8.5 Other Samples

9 Global Predictive Presymptomatic Testing Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Diagnostic Laboratories
• 9.4 Research & Academic Institutions
• 9.5 Specialty Clinics
• 9.6 Other End Users

10 Global Predictive Presymptomatic Testing Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 23andMe
• 12.2 Abbott Laboratories Inc.
• 12.3 Quest Diagnostics Inc.
• 12.4 Positive Bioscience
• 12.5 Color Genomics
• 12.6 Gene by Gene
• 12.7 Mapmygenome
• 12.8 Myriad Genetics
• 12.9 BioAxis DNA Research Center Private Limited
• 12.10 Direct Laboratory Services LLC
• 12.11 Pathway Genomics Corporation
• 12.12 Ambry Genetics Corporation
• 12.13 Akonni Biosystems
• 12.14 Element Biosciences
• 12.15 Eurofins Scientific
• 12.16 NGeneBio